ADMA ADMA Biologics Inc gains 20% Nov 29, 2017

ADMA Biologics, Inc., a late stage biopharmaceutical company, develops, manufactures, and intends to market specialty plasma-based biologics for the treatment and prevention of infectious diseases. Its lead product candidate is RI-002, a plasma-derived, polyclonal immune globulin intravenous that is in Phase III clinical study for the treatment of primary immune deficiency disease. The company also operatesADMA BioCenters Georgia, Inc, which is a plasma collection center. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey. http://www.priceseries.com/trade/ADMA-ADMA-Biologics-Inc-stock-gains-20-percent-a-Trade-Record-by-priceSeries-2017111320171129.html